Compare Ecolab Inc. (ECL) vs Medtronic PLC (MDT) Price & Performance

Ecolab (ECL) trades at $281.69, up 0.31% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $326.38. The company reported revenue of $16.08B in 2025 with a net income margin of 12.57%, and recent earnings have mostly met or exceeded expectations. Strong institutional buying and insider purchases, alongside positive news coverage highlighting its dividend growth and essential business model, support a constructive outlook.

The stock presents a favorable risk-reward profile given its steady revenue growth, high profitability, and analyst optimism, though elevated valuation ratios and increased debt from the CoolIT acquisition pose risks. The upcoming Q3 2026 earnings report on October 27, 2026, will be a key catalyst for near-term price direction.

Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.

MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.